Oxford Cannabinoid Technologies is pleased to announce that the Company's management team will conduct a live presentation to retail investors introducing the company following their recent admission to the London Stock Exchange and presenting the outlook for the year ahead.

Date: Thursday 10th June

Time: 1pm

Register here

Oxford Cannabinoid Technologies Holdings plc (“OCT”) is a UK-based next generation cannabis pharmaceutical company focussed on the development cannabinoid-based prescription medicines to target indications in the £42.5bn pain market, with regulatory marketing approval from agencies including the FDA, EMA and MHRA. Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs. To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.

Register here


Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here